Analysis of Chromatin Pathways as Regulators of High Grade Glioma Gene Expression Patterns

Email Principal Investigator
Ongoing
Data
Epigenetic Dysregulation
HGG
DIPG
Asset 1.png
Anastas-Jamie.jpg

Jamie Anastas

Boston Children's Hospital
Boston, MA USA

CBTN Data

About this

Project

Patients with high grade gliomas (HGG) face considerable treatment challenges and comprehensive research is needed to find new therapeutic options. Using the Pediatric Brain Tumor Atlas, researchers will identify genes that are expressed differently in patient-derived tumor samples compared to normal tissue samples. Gene expression, the process by which the genetic information is used to direct production of proteins in the body, is crucial in understanding the similarities and differences across tumor types. Additionally, these genetic signatures will be used in comparison to lab-grown tumor cell lines that have been genetically manipulated or treated with various drugs. Researchers hope to analyze these comparisons and identify patterns in gene expression that could pave the way for the development of new therapies.

Ask The

Scientists

Ask the scientists

What are the goals of this project?

Researchers will identify and compare tumor samples, normal tissue samples, and lab grown tumor samples in an effort to identify patterns in gene expression.

What is the impact of this project?

The identification of patterns in gene expression across tumor types could lead to the development of new targeted therapies.

Why is the CBTN request important to this project?

The breadth and depth of data available through the Pediatric Brain Tumor Atlas will be pivotal in supporting this project.

Specimen Data

The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.

Explore the data in these informatics portals

Cavativa-Logo.png

Meet The

Team

Anastas-Jamie.jpg

Jamie Anastas, PhD

Dr. Anastas is studying how mutations in chromatin-associated factors affect heterochromatin organization in pediatric cancer.

Boston-Children-Hospital.jpg

Boston Children's Hospital

Boston, MA USA
Default person avatar

Principal Investigator

Mariella Filbin, MD, PhD

Dr. Mariella Filbin is the Research Co-Director at Harvard Medical School. She received her MD and PhD in biochemistry and molecular biology from the Medical University of Graz, Austria. Following graduation she completed her pediatric residency at the Boston Children's Hospital and completed a fell

101032_1331178.jpg.2000x1333_q95_crop-smart_upscale.jpg

Harvard Medical School

Boston, MA
Default person avatar

David Root, PhD

Dr. David Root is the Senior Director of the Genetic Perturbation Platform and Functional Genomics Consortium at the Broad Institute of MIT and Harvard. He received his PhD in physical chemistry from Stanford University. He was previously assistant professor of physical chemistry at Swarthmore Colle

Default person avatar

Phil Cole, MD, PhD

Dr. Phil Cole is a Professor of Medicine and Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He received his MD and PhD from Johns Hopkins where he pursued research in bioorganiz chemistry. Following graduation he completed post-doctoral training at Harvard Medical School

101032_1331178.jpg.2000x1333_q95_crop-smart_upscale.jpg

Harvard Medical School

Boston, MA
Shi-Yang.original.jpg

Yang Shi, PhD

Yang Shi joined Harvard Medical School as an assistant professor in 1991 and was appointed a Professor of Pathology in 2004. He is currently a Professor of Cell Biology. He is also the Merton Bernfield Professor of Neonatology in the Division of Newborn Medicine at Children’s Hospital Boston. Yang

101032_1331178.jpg.2000x1333_q95_crop-smart_upscale.jpg

Harvard Medical School

Boston, MA
Default person avatar

Todd Golub, MD

Dr. Todd Golub is the Core Institute Member, Chief Scientific Officer, and Director of the Cancer Program at Broad Institute. He received his medical degree from the University of Chicago Pritzker School of Medicine. Following graduation, he completed his internship, residency, and fellowship traini

Default person avatar

Jay Kalin, PhD

Default institution image

The Janssen Pharmaceutical Companies of Johnson and Johnson

1125 Trenton Harbourton Rd, Titusville, NJ 08560
Default person avatar

Federica Piccioni, PhD

broad 2.jpg

Broad Institute of MIT and Harvard

415 Main Street Cambridge, MA 02142